By: Benzinga
UPDATE: Wedbush Raises PT to $8 on Celldex Therapeutics on Rindopepimut Outlook
Wedbush maintained Celldex Therapeutics (NASDAQ: CLDX ) with an Outperform rating and raised the price target from $8.00 to $20.00. Wedbush analyst Gregory R. Wade noted, "We are increasing our price target to $20 from $8 based upon revised launch and peak penetration assumptions as emerging data to suggest a
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here